Suppr超能文献

视网膜母细胞瘤治疗中动脉内化疗继发的睫状睫毛脱落

Ciliary Madarosis Secondary to Intra-Arterial Chemotherapy for Retinoblastoma Treatment.

作者信息

Watts-Santos Anabella, Ancona-Lezama David Arturo, Figueroa-Sanchez Jose A, Mares-Custodio Daniela, Garza-Rodríguez Verónica

机构信息

VG Skin Clinic Derma and Laser, San Pedro Garza Garcia, Mexico.

Eye Cancer Institute, Guadalajara, Mexico.

出版信息

Skin Appendage Disord. 2024 Jun;10(3):167-171. doi: 10.1159/000535826. Epub 2024 Jan 29.

Abstract

BACKGROUND

Retinoblastoma is the most common intraocular tumor in the pediatric population. Its main therapeutic objectives are to avoid fatal outcomes and preserve vision as much as possible. Intra-arterial chemotherapy (IAC) improves drug delivery and reduces possible systemic adverse effects. This modality allows direct administration of chemotherapeutic agents to intraocular malignancies via the ophthalmic artery (OA), proving to be a feasible and effective method for globe salvage. Most side effects of IAC are local, including eyelash loss of the nasal portion of the eyelid.

SUMMARY

We performed a comprehensive review to analyze data regarding ciliary madarosis in patients diagnosed with retinoblastoma treated with IAC. We describe 9 studies with a total of 637 eyes with retinoblastoma that underwent IAC, of which 45 cases presented madarosis. In chemotherapy-induced alopecia, there is hair shaft thinning and breakage. On trichoscopy, the remaining end of the fractured hair will be observed as black dots. Differential diagnoses must include alopecia areata and trichotillomania.

KEY MESSAGES

Ciliary madarosis secondary to IAC, although transitional, may cause discomfort in patients and family members. Physical examination, as well as a trichoscopic evaluation of the affected area, can help in reaching a prompt diagnosis and prognosis for this particular alopecia.

摘要

背景

视网膜母细胞瘤是儿童人群中最常见的眼内肿瘤。其主要治疗目标是避免致命后果并尽可能保留视力。动脉内化疗(IAC)可改善药物递送并减少可能的全身不良反应。这种方式允许通过眼动脉(OA)将化疗药物直接施用于眼内恶性肿瘤,被证明是一种可行且有效的挽救眼球方法。IAC的大多数副作用是局部的,包括眼睑鼻侧睫毛脱落。

总结

我们进行了一项全面综述,以分析接受IAC治疗的视网膜母细胞瘤患者中睫毛脱落的数据。我们描述了9项研究,共有637只患有视网膜母细胞瘤的眼睛接受了IAC治疗,其中45例出现了睫毛脱落。在化疗引起的脱发中,会出现毛干变细和断裂。在毛发镜检查中,断裂毛发的剩余末端将被观察为黑点。鉴别诊断必须包括斑秃和拔毛癖。

关键信息

IAC继发的睫毛脱落虽然是暂时的,但可能会给患者及其家属带来不适。体格检查以及对受影响区域的毛发镜评估有助于对这种特殊的脱发做出快速诊断和预后判断。

相似文献

1
Ciliary Madarosis Secondary to Intra-Arterial Chemotherapy for Retinoblastoma Treatment.
Skin Appendage Disord. 2024 Jun;10(3):167-171. doi: 10.1159/000535826. Epub 2024 Jan 29.
2
Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma.
Indian J Ophthalmol. 2023 Feb;71(2):436-443. doi: 10.4103/ijo.IJO_1388_22.
3
Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy.
J Fr Ophtalmol. 2015 Jun;38(6):542-9. doi: 10.1016/j.jfo.2015.03.004. Epub 2015 May 14.
5
Salvage Intra-arterial Chemotherapy for Recurrent or Persistent Intraocular Retinoblastoma: A Study of 24 Eyes.
Ophthalmol Retina. 2023 Mar;7(3):275-281. doi: 10.1016/j.oret.2022.09.006. Epub 2022 Oct 3.
8
Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.
Ophthalmology. 2014 Jul;121(7):1453-60. doi: 10.1016/j.ophtha.2014.01.026. Epub 2014 Mar 21.
9
Comparing internal versus external carotid artery branch delivery of intraarterial chemotherapy for the treatment of retinoblastoma.
Graefes Arch Clin Exp Ophthalmol. 2023 Sep;261(9):2679-2687. doi: 10.1007/s00417-023-06037-w. Epub 2023 Apr 3.

本文引用的文献

1
Eyebrow and Eyelash Alopecia: A Clinical Review.
Am J Clin Dermatol. 2023 Jan;24(1):55-67. doi: 10.1007/s40257-022-00729-5. Epub 2022 Oct 2.
2
The Addition of Topotecan to Melphalan in the Treatment of Retinoblastoma with Intra-arterial Chemotherapy.
Ophthalmol Retina. 2021 Aug;5(8):824-830. doi: 10.1016/j.oret.2020.11.007. Epub 2020 Nov 19.
3
Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review.
Int J Dermatol. 2018 Dec;57(12):1417-1424. doi: 10.1111/ijd.13906. Epub 2018 Jan 29.
5
Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.
PLoS One. 2016 Jan 12;11(1):e0146582. doi: 10.1371/journal.pone.0146582. eCollection 2016.
6
Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience.
J Pediatr Hematol Oncol. 2016 Jan;38(1):65-9. doi: 10.1097/MPH.0000000000000471.
7
Intra-arterial chemotherapy with melphalan for intraocular retinoblastoma.
Br J Ophthalmol. 2013 Sep;97(9):1219-21. doi: 10.1136/bjophthalmol-2013-303267. Epub 2013 Jul 12.
8
Pathobiology of chemotherapy-induced hair loss.
Lancet Oncol. 2013 Feb;14(2):e50-9. doi: 10.1016/S1470-2045(12)70553-3.
9
Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments.
Acta Ophthalmol. 2013 Jun;91(4):335-42. doi: 10.1111/j.1755-3768.2011.02296.x. Epub 2012 Jan 23.
10
Chemosurgery for retinoblastoma: what we know after 5 years.
Arch Ophthalmol. 2011 Nov;129(11):1492-4. doi: 10.1001/archophthalmol.2011.354.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验